SOPHiA GENETICS (NASDAQ:SOPH) Sees Strong Trading Volume - Here's What Happened

Key Points

• SOPHiA GENETICS shares traded at $8.65 amid elevated volume, with 134,486 shares changing hands—43% below the prior session’s volume.
• Analyst sentiment is mixed: the stock has a consensus “Hold” rating and a $10.00 average price target, while HC Wainwright and BTIG Research maintained “Buy” ratings and raised their targets.
• The company beat revenue expectations but missed on earnings, reporting quarterly revenue of $23.31 million and an EPS loss of $0.26 versus the $0.21 consensus loss; insiders have sold 318,592 shares over the past 90 days.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) shares saw unusually-high trading volume on Monday . 134,486 shares were traded during mid-day trading, a decline of 43% from the previous session's volume of 234,441 shares.The stock last traded at $8.65 and had previously closed at $8.65.

Analyst Ratings Changes

Several research analysts have recently commented on SOPH shares. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. HC Wainwright lifted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, BTIG Research upped their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $10.00.

SOPHiA GENETICS Price Performance

The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The stock's 50 day moving average price is $6.18 and its two-hundred day moving average price is $5.32. The firm has a market capitalization of $716.84 million, a price-to-earnings ratio of -7.44 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. On average, equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Insider Transactions at SOPHiA GENETICS

In related news, insider Zhenyu Xu sold 17,000 shares of the business's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the transaction, the insider owned 590,887 shares of the company's stock, valued at approximately $4,307,566.23. The trade was a 2.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ross Muken sold 9,838 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.22, for a total value of $51,354.36. Following the sale, the chief executive officer owned 670,651 shares of the company's stock, valued at approximately $3,500,798.22. The trade was a 1.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 318,592 shares of company stock worth $1,952,315. Company insiders own 4.88% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter worth $50,000. Squarepoint Ops LLC acquired a new position in SOPHiA GENETICS during the 3rd quarter valued at $49,000. Perkins Capital Management Inc. acquired a new position in SOPHiA GENETICS during the 4th quarter valued at $49,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS during the 4th quarter valued at $54,000. Finally, XTX Topco Ltd bought a new stake in SOPHiA GENETICS in the 4th quarter valued at $55,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source